Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement under which Sobi® ...

Ionis has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen.

Ionis Pharmaceuticals has entered a licence agreement with Sobi in which the latter obtains exclusive rights to commercialise olezarsen intended for familial chylomicronaemia syndrome (FCS ...

Ionis will continue to independently commercialize TRYNGOLZA™ (olezarsen) in the U.S. – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it has entered into a license agreement ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

The agreement follows the U.S. Food and Drug Administration’s approval of olezarsen, branded as TRYNGOLZA™, in December 2024 as the sole treatment for FCS in the U.S. With a robust current ...

Biogen ( NASDAQ: BIIB) said on Wednesday that the U.S. FDA has granted Fast Track designation to BIIB080, its antisense ...

Ionis Pharmaceuticals (IONS) announced that it has entered into a license agreement under which Sobi received exclusive rights in countries ...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), a $5.1 billion market cap biotechnology company currently trading near its 52-week low, has announced a licensing agreement granting Sobi® exclusive rights ...